Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
147.12
-1.29 (-0.87%)
At close: May 29, 2026, 4:00 PM EDT
147.46
+0.34 (0.23%)
After-hours: May 29, 2026, 7:00 PM EDT
BDX Revenue
Becton, Dickinson and Company had revenue of $4.71B in the quarter ending March 31, 2026, with 5.22% growth. This brings the company's revenue in the last twelve months to $21.37B, up 6.43% year-over-year. In the fiscal year ending September 30, 2025, Becton, Dickinson and Company had annual revenue of $21.84B with 8.24% growth.
Revenue (ttm)
$21.37B
Revenue Growth
+6.43%
P/S Ratio
1.82
Revenue / Employee
$308,708
Employees
72,000
Market Cap
40.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 21.84B | 1.66B | 8.24% |
| Sep 30, 2024 | 20.18B | 806.00M | 4.16% |
| Sep 30, 2023 | 19.37B | 502.00M | 2.66% |
| Sep 30, 2022 | 18.87B | -261.00M | -1.36% |
| Sep 30, 2021 | 19.13B | 3.06B | 19.02% |
| Sep 30, 2020 | 16.07B | -1.22B | -7.03% |
| Sep 30, 2019 | 17.29B | 1.31B | 8.18% |
| Sep 30, 2018 | 15.98B | 3.89B | 32.17% |
| Sep 30, 2017 | 12.09B | -390.00M | -3.12% |
| Sep 30, 2016 | 12.48B | 2.20B | 21.41% |
| Sep 30, 2015 | 10.28B | 1.84B | 21.74% |
| Sep 30, 2014 | 8.45B | 392.00M | 4.87% |
| Sep 30, 2013 | 8.05B | 346.00M | 4.49% |
| Sep 30, 2012 | 7.71B | 124.00M | 1.64% |
| Sep 30, 2011 | 7.58B | 459.61M | 6.45% |
| Sep 30, 2010 | 7.12B | 137.67M | 1.97% |
| Sep 30, 2009 | 6.99B | 89.10M | 1.29% |
| Sep 30, 2008 | 6.90B | 614.78M | 9.79% |
| Sep 30, 2007 | 6.28B | 544.82M | 9.49% |
| Sep 30, 2006 | 5.74B | 397.19M | 7.44% |
| Sep 30, 2005 | 5.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medline | 29.14B |
| Baxter International | 11.32B |
| Alcon | 10.63B |
| Intuitive Surgical | 10.58B |
| Solventum | 8.26B |
| ResMed | 5.54B |
| The Cooper Companies | 4.15B |
| Align Technology | 4.10B |
BDX News
- 9 days ago - BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System - PRNewsWire
- 12 days ago - These 5 Stocks Have 50 Years of Dividend Growth—Here's How to Find More - Investopedia
- 12 days ago - Peter Menziuso Named EVP and President, BD Interventional - PRNewsWire
- 18 days ago - Becton, Dickinson and Company Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 19 days ago - Becton Dickinson price target raised to $204 from $202 at Barclays - TheFly
- 21 days ago - Becton, Dickinson and Company Q2 Earnings Call Highlights - MarketBeat
- 23 days ago - Becton Dickinson names Vitor Roque CFO - TheFly
- 23 days ago - Becton, Dickinson and Company Earnings Call Transcript: Q2 2026 - Transcripts